- Simris Biologics is advancing a pipeline of best-in-class ADC payloads, derived from proprietary cyanobacterial technologies.
- Our unparalleled strain library is a rich source of novel payload candidates.
- Our lead Microcystin variant has demonstrated industry-competitive efficacy and a promising safety profile.
- We aim to create significant value through early-stage licensing deals with leading biopharma partners.
ANTIBODY DRUG CONJUGATES
Simris is building a powerful ADC payload platform designed to deliver enhanced efficacy, superior safety, and greater versatility.
CYANOBACTERIAL TOXIN STANDARDS AND REAGENTS
Our range of high-quality standards and reagents are trusted by water authorities around the world.